MedTrace Logo

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

NCT01125046 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-01-22

Study results available
· View outcomes & findings →

Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progression meningiomas.

Conditions

  • Acoustic Schwannoma
  • Adult Anaplastic Meningioma
  • Adult Ependymoma
  • Adult Grade I Meningioma
  • Adult Grade II Meningioma
  • Adult Meningeal Hemangiopericytoma
  • Adult Papillary Meningioma
  • Neurofibromatosis Type 1
  • Neurofibromatosis Type 2
  • Recurrent Adult Brain Tumor

Interventions

BIOLOGICAL

bevacizumab

Given IV

Sponsors & Collaborators

Principal Investigators

  • Priya Kumthekar, MD · Northwestern University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-17
Primary Completion
2014-03-10
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01125046 on ClinicalTrials.gov